MICHAEL SEVERINO Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for MICHAEL SEVERINO.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of MICHAEL SEVERINO. MICHAEL SEVERINO is EVP, R&D and CSO in AbbVie Inc. ($ABBV) and Vice Chairman in AbbVie Inc. ($ABBV) and Director in Avantor, Inc. ($AVTR).
Latest Insider Trading Transactions of MICHAEL SEVERINO
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 02 2021 | ABBV | AbbVie Inc. | SEVERINO MICHAEL | Vice Chairman | Payment of Exercise | F | 107.74 | 29,077 | 3,132,756 | 103,835 | 132.9 K to 103.8 K (-21.88 %) |
| Mar 01 2021 | AVTR | Avantor, Inc. | SEVERINO MICHAEL | Director | Grant | A | 0.00 | 7,236 | 0 | 17,258 | 10 K to 17.3 K (+72.20 %) |
| Nov 06 2020 | ABBV | AbbVie Inc. | SEVERINO MICHAEL | Vice Chairman | Sell | S | 93.61 | 90,679 | 8,488,461 | 67,281 | 158 K to 67.3 K (-57.41 %) |
| Apr 24 2020 | AVTR | Avantor, Inc. | SEVERINO MICHAEL | Director | Grant | A | 0.00 | 10,022 | 0 | 10,022 | 0 to 10 K |
| Apr 24 2020 | AVTR | Avantor, Inc. | SEVERINO MICHAEL | Director | Grant | A | 0.00 | 10,022 | 0 | 10,022 | 0 to 10 K |
| Mar 03 2020 | ABBV | AbbVie Inc. | SEVERINO MICHAEL | Vice Chairman | Payment of Exercise | F | 85.42 | 33,492 | 2,860,887 | 157,960 | 191.5 K to 158 K (-17.49 %) |
| Feb 22 2019 | ABBV | AbbVie Inc. | SEVERINO MICHAEL | Vice Chairman | Option Exercise | A | 79.02 | 64,485 | 5,095,605 | 64,485 | |
| Feb 22 2019 | ABBV | AbbVie Inc. | SEVERINO MICHAEL | Vice Chairman | Grant | A | 0.00 | 8,565 | 0 | 142,567 | 134 K to 142.6 K (+6.39 %) |
| Feb 22 2019 | ABBV | AbbVie Inc. | SEVERINO MICHAEL | Vice Chairman | Grant | A | 0.00 | 14,989 | 0 | 134,002 | 119 K to 134 K (+12.59 %) |
| Feb 22 2019 | ABBV | AbbVie Inc. | SEVERINO MICHAEL | Vice Chairman | Grant | A | 0.00 | 15,375 | 0 | 119,013 | 103.6 K to 119 K (+14.84 %) |
| Feb 22 2019 | ABBV | AbbVie Inc. | SEVERINO MICHAEL | Vice Chairman | Grant | A | 0.00 | 21,357 | 0 | 103,638 | 82.3 K to 103.6 K (+25.96 %) |
| Aug 21 2018 | ABBV | AbbVie Inc. | SEVERINO MICHAEL | EVP, R&D and CSO | Sell | S | 97.91 | 29,200 | 2,859,109 | 82,281 | 111.5 K to 82.3 K (-26.19 %) |
| Aug 21 2018 | ABBV | AbbVie Inc. | SEVERINO MICHAEL | EVP, R&D and CSO | Sell | S | 96.97 | 20,800 | 2,016,951 | 111,481 | 132.3 K to 111.5 K (-15.72 %) |
| Mar 02 2018 | ABBV | AbbVie Inc. | SEVERINO MICHAEL | EVP, R&D and CSO | Sell | S | 117.93 | 2,643 | 311,684 | 132,281 | 134.9 K to 132.3 K (-1.96 %) |
| Mar 02 2018 | ABBV | AbbVie Inc. | SEVERINO MICHAEL | EVP, R&D and CSO | Payment of Exercise | F | 118.26 | 27,683 | 3,273,792 | 134,924 | 162.6 K to 134.9 K (-17.02 %) |
| Feb 16 2018 | ABBV | AbbVie Inc. | SEVERINO MICHAEL | EVP, R&D and CSO | Option Exercise | A | 114.36 | 46,320 | 5,297,155 | 46,320 | |
| Feb 16 2018 | ABBV | AbbVie Inc. | SEVERINO MICHAEL | EVP, R&D and CSO | Grant | A | 0.00 | 14,991 | 0 | 162,607 | 147.6 K to 162.6 K (+10.16 %) |
| Feb 16 2018 | ABBV | AbbVie Inc. | SEVERINO MICHAEL | EVP, R&D and CSO | Grant | A | 0.00 | 17,319 | 0 | 147,616 | 130.3 K to 147.6 K (+13.29 %) |
| Feb 16 2018 | ABBV | AbbVie Inc. | SEVERINO MICHAEL | EVP, R&D and CSO | Grant | A | 0.00 | 15,375 | 0 | 130,297 | 114.9 K to 130.3 K (+13.38 %) |
| Nov 13 2017 | ABBV | AbbVie Inc. | SEVERINO MICHAEL | EVP, R&D and CSO | Sell | S | 94.69 | 25,633 | 2,427,212 | 114,922 | 140.6 K to 114.9 K (-18.24 %) |
| Jun 05 2017 | ABBV | AbbVie Inc. | SEVERINO MICHAEL | EVP, R&D and CSO | Payment of Exercise | F | 66.71 | 21,576 | 1,439,335 | 140,555 | 162.1 K to 140.6 K (-13.31 %) |
| Feb 21 2017 | ABBV | AbbVie Inc. | SEVERINO MICHAEL | EVP, R&D and CSO | Option Exercise | A | 61.36 | 100,100 | 6,142,136 | 100,100 | |
| Feb 21 2017 | ABBV | AbbVie Inc. | SEVERINO MICHAEL | EVP, R&D and CSO | Grant | A | 0.00 | 15,375 | 0 | 192,830 | 177.5 K to 192.8 K (+8.66 %) |
| Feb 21 2017 | ABBV | AbbVie Inc. | SEVERINO MICHAEL | EVP, R&D and CSO | Grant | A | 0.00 | 34,173 | 0 | 177,455 | 143.3 K to 177.5 K (+23.85 %) |
| Jun 03 2016 | ABBV | AbbVie Inc. | SEVERINO MICHAEL | EVP, R&D and CSO | Payment of Exercise | F | 62.83 | 21,574 | 1,355,494 | 143,282 | 164.9 K to 143.3 K (-13.09 %) |
| Mar 02 2016 | ABBV | AbbVie Inc. | SEVERINO MICHAEL | EVP, R&D and CSO | Option Exercise | A | 54.86 | 91,990 | 5,046,571 | 91,990 | |
| Mar 02 2016 | ABBV | AbbVie Inc. | SEVERINO MICHAEL | EVP, R&D and CSO | Payment of Exercise | F | 56.00 | 8,053 | 450,968 | 164,856 | 172.9 K to 164.9 K (-4.66 %) |
| Feb 22 2016 | ABBV | AbbVie Inc. | SEVERINO MICHAEL | EVP, R&D and CSO | Option Exercise | A | 54.86 | 91,990 | 5,046,571 | 91,990 | |
| Jun 04 2015 | ABBV | AbbVie Inc. | SEVERINO MICHAEL | EVP, R&D and CSO | Payment of Exercise | F | 66.93 | 21,576 | 1,444,082 | 172,909 | 194.5 K to 172.9 K (-11.09 %) |
| Feb 23 2015 | ABBV | AbbVie Inc. | SEVERINO MICHAEL | EVP, R&D and CSO | Option Exercise | A | 58.88 | 104,480 | 6,151,782 | 104,480 | |
| Feb 23 2015 | ABBV | AbbVie Inc. | SEVERINO MICHAEL | EVP, R&D and CSO | Grant | A | 0.00 | 52,860 | 0 | 194,485 | 141.6 K to 194.5 K (+37.32 %) |
| Jun 04 2014 | ABBV | AbbVie Inc. | SEVERINO MICHAEL | EVP, R&D and CSO | Option Exercise | A | 54.44 | 74,309 | 4,045,382 | 74,309 | |
| Jun 04 2014 | ABBV | AbbVie Inc. | SEVERINO MICHAEL | EVP, R&D and CSO | Grant | A | 0.00 | 141,625 | 0 | 141,625 | 0 to 141.6 K |
Page: 1